Zyvox Related Published Studies
Well-designed clinical trials related to Zyvox (Linezolid)
Health economic evaluation of patients treated for nosocomial pneumonia caused by
methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter
randomized clinical trial of vancomycin and linezolid. [2014]
Platelet profile in patients with acute bacterial skin and skin structure
infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH
clinical trials. [2014]
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a
randomized, controlled study. [2012]
A randomised, double-blind trial comparing ceftobiprole medocaril with
ceftriaxone with or without linezolid for the treatment of patients with
community-acquired pneumonia requiring hospitalisation. [2012]
Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. [2011.12.02]
Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. [2011.07]
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. [2011.06]
Randomized, double-blind, phase II, multicenter study evaluating the
safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared
with linezolid for treatment of acute bacterial skin and skin structure
infection. [2011]
A randomized, double-blind phase 2 study comparing the efficacy and safety of an
oral fusidic acid loading-dose regimen to oral linezolid for the treatment of
acute bacterial skin and skin structure infections. [2011]
Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. [2010.12]
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. [2010.06]
Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. [2010.01]
[Linezolid versus vancomycin in the treatment of pneumonia caused by
Gram-positive cocci: meta-analysis of randomised controlled trials]. [Article in Chinese] [2010]
Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? [2009.05]
Affect of linezolid in ventilator-associated pneumonia caused by MRSA. [2009.03]
Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. [2009.01.15]
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. [2008.12.01]
Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. [2008.12]
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. [2008.09]
Linezolid for the treatment of infections caused by Gram-positive pathogens in China. [2008.09]
Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. [2008.02]
Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain. [2007.08]
Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. [2006.08]
Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. [2006.06]
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. [2006.03.01]
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). [2005.12]
Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. [2005.09]
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. [2005.06]
Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. [2005.04]
Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. [2005.03]
Linezolid eradicates MRSA better than vancomycin from surgical-site infections. [2004.12]
Effect of oral linezolid on the pressor response to intravenous tyramine. [2004.11]
Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. [2004.06]
An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. [2004.04]
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. [2004.04]
Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. [2004.02]
Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. [2004.02]
Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. [2004.02]
Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. [2004.01.01]
Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. [2003.12.15]
Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. [2003.12]
Cytokines in periradicular lesions: the effect of linezolid treatment. [2003.10]
Hematologic effects of linezolid in young children. [2003.09]
Linezolid for the treatment of complicated skin and skin structure infections in children. [2003.09]
Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. [2003.09]
Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. [2003.09]
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. [2003.08]
Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial. [2003.06]
Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. [2003.05]
Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. [2003.04]
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. [2003.03]
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. [2003.03]
Linezolid: in infants and children with severe Gram-positive infections. [2003]
Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. [2002.11]
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. [2002.06.01]
Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. [2002.06]
Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. [2002.02]
Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. [2002]
[Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study] [2002]
Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. [2001.08]
Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. [2001.05]
Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. [2001.05]
Linezolid absolute bioavailability and the effect of food on oral bioavailability. [2001.04]
Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections. [2001.03]
Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. [2001.03]
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. [2001.02.01]
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. [2001]
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. [2000.12]
A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. [1999.12]
Well-designed clinical trials possibly related to Zyvox (Linezolid)
Once-weekly dalbavancin versus daily conventional therapy for skin infection. [2014]
Meta-analysis of randomized controlled trials of vancomycin for the treatment of
patients with gram-positive infections: focus on the study design. [2012]
New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis,
treatment and resistance. [2012]
Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. [2011.02]
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. [2011.02]
Phase 2, randomized, double-blind, dose-ranging study evaluating the safety,
tolerability, population pharmacokinetics, and efficacy of oral torezolid
phosphate in patients with complicated skin and skin structure infections. [2011]
Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. [2010.09.01]
Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. [2010.01.15]
Safety and efficacy of intravenous tigecycline in subjects with secondary
bacteremia: pooled results from 8 phase III clinical trials. [2010]
Dalbavancin. [2008]
Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. [2005.02]
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. [2004.04]
Other research related to Zyvox (Linezolid)
Impact of patient characteristics and infection type on clinical outcomes of
patients who received linezolid or vancomycin for complicated skin and skin
structure infections caused by methicillin-resistant Staphylococcus aureus: a
pooled data analysis. [2014]
Linezolid for the treatment of drug-resistant tuberculosis in children: a review
and recommendations. [2014]
Linezolid versus vancomycin for skin and soft tissue infections. [2013]
Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a
systematic review and meta-analysis. [2013]
Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus
infection: a meta-analysis of randomised controlled trials. [2013]
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. [2012]
Clinical efficacy of oral linezolid compared with intravenous vancomycin for the
treatment of methicillin-resistant Staphylococcus aureus-complicated skin and
soft tissue infections: a retrospective, propensity score-matched, case-control
analysis. [2012]
Linezolid and vancomycin in treatment of lower-extremity complicated skin and
skin structure infections caused by methicillin-resistant Staphylococcus aureus
in patients with and without vascular disease. [2012]
Comparison of serotonin toxicity with concomitant use of either linezolid or
comparators and serotonergic agents: an analysis of Phase III and IV randomized
clinical trial data. [2012]
Linezolid versus vancomycin antibiotic lock solution for the prevention of
nontunneled catheter-related blood stream infections in hemodialysis patients: a
prospective randomized study. [2012]
Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection. [2011.12]
Linezolid versus Vancomycin Antibiotic Lock Solution for the Prevention of Nontunneled Catheter-related Blood Stream Infections in Hemodialysis Patients: A Prospective Randomized Study. [2011.11.10]
Susceptibility to Tigecycline and Linezolid Among Gram-Positive Isolates Collected in the United States as Part of the Tigecycline Evaluation and Surveillance Trial (TEST) Between 2004 and 2009. [2011.11.09]
Clinical Outcomes of Linezolid vs Vancomycin in Methicillin-Resistant Staphylococcus aureus Ventilator-Associated Pneumonia: Retrospective Analysis. [2011.11]
Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. [2011.09.15]
Implant stability in the treatment of MRSA bone implant infections with linezolid versus vancomycin in a rabbit model. [2011.08.03]
Does linezolid modulate lung innate immunity in a murine model of methicillin-resistant Staphylococcus aureus pneumonia? [2011.08]
Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. [2011.07]
Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. [2011.07]
Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative - an investigation using behavioral tests battery of depression. [2011.06.17]
|
